Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer

Chest

Volumn 113, Issue 1 SUPPL., 1998, Pages 13S-16S

  Bonomi, Philip ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IPROPLATIN; MITOMYCIN; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0031965401     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.1_Supplement.13S     Document Type: Article

References (16)

1. Bonomi P. Brief overview of combination chemotherapy in non-small cell lung cancer. Semin Oncol 1986; 13(suppl 3):89-91
2. Ruckdeschel JC, Finkelstein DN, Ettinger DS, et al. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST:2575, generation V-a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 1985; 3:72-79
3. Ruckdeschel JC, Finkelstein DN, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986; 4:14-22
4. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11:1866-72
5. Bonomi P, Finkelstein DN, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7:1602-13
6. Kreisman H, Ginsberg S, Propert KS, et al. Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Cancer Treat Rep 1987; 71:1049-52
7. Finkelstein DN, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4:702-09
8. Bonomi P, Finkelstein D, Chang A. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: an Eastern Cooperative Oncology Group study. Am J Clin Oncol 1994; 17:215-17
9. Chang AY, Kim K, Click J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85:388-94
10. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85:384-88
11. Bonomi P, Kim K, Chang A. et al. Phase III trial comparing etoposide-cisplatin versus Taxol with cisplatin-G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group trial [abstract]. Proc Am Soc Clin Oncol 1996; 15:382
12. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6
13. Rowinsky EK, Chandra V, Forastierre A, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulo-cyte colony stimulating factor: neuromuscular toxicity is dose limiting. J Clin Oncol 1993; 11:2010-20
14. Lilenbaum RC, Green MP. Novel chemotherapeutic agents in treatment of non-small cell lung cancer. J Clin Oncol 1993; 11:1391-1402
15. Langer CJ, Leighton JC, Comis RI, et al. Paclitaxel and carboplarin in combination in the treatment of advanced non-small cell lung cancer: a phase II response and survival analysis. J Clin Oncol 1995; 13:1860-70
16. Muggia EM, Vofai D, Natale R, et al. Paclitaxel 3 hour infusion given alone and combined with carboplatin: preliminary results of dose escalation studies. Semin Oncol 1995; 15:382-87